Newland Pharmaceutical (301277.SZ) has obtained the approval notice for the listing application of chemical raw materials.

Newland Pharmaceutical (301277.SZ) announced that on September 24, 2024, the company received the "Chemical Raw Materials Market Application Approval Notification Letter" for the approval and issuance of the raw materials esomeprazole sodium and tadalafil by the National Medical Products Administration. It is reported that esomeprazole sodium is a proton pump inhibitor that inhibits H+/K+-ATPase in gastric cells, providing inhibition of both basal and stimulated gastric acid secretion. It can treat gastric and esophageal reflux diseases, gastric ulcers, duodenal ulcers caused by excessive gastric acid secretion. It can also be used in combination with antibiotics to treat Helicobacter pylori infections in the stomach, showing significant effectiveness in the treatment of acid-related gastric diseases. Tadalafil is a phosphodiesterase inhibitor that increases intracellular cGMP levels by inhibiting PDE5 on vascular smooth muscle. It has a significant therapeutic effect on male erectile dysfunction, and can also be used in the treatment of pulmonary arterial hypertension due to its vasodilator effects on the cardiovascular and pulmonary arteries.